// App-Quantinova.ai

: Cardiovascular (CV) Safety and Severe Hypoglycemia Benefit of Insulin Degludec vs. Insulin Glargine U100 in Older Patients (=65 Years) with Type 2 Diabetes (T2D)—Observations from DEVOTE

Researchers

Presenter

  • RICHARD E. PRATLEY

Principal Investigators

  • SCOTT S. EMERSON

  • EDWARD FRANEK

  • MATTHEW P. GILBERT

  • STEVEN P. MARSO

  • DARREN K. MCGUIRE

  • THOMAS R. PIEBER

  • NEIL R. POULTER

  • CHARLOTTE T. HANSEN

  • MELISSA V. HANSEN

  • THOMAS MARK

  • ALAN C. MOSES

  • BERNARD ZINMAN

Medical Centers

  • N/A

Locations

  • United States

  • Poland

  • Austria

  • United Kingdom

  • Denmark

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

  • Genetic Disorder

Disease

  • N/A

Biomarkers

  • Insulin

Drug/Treatment

  • Insulin glargine

  • Insulin degludec

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved